Business Context and Reporting Period
This Form 8-K Current Report from Natera, Inc. (NTRA) covers the period ending March 6, 2020. The filing addresses the termination of a material definitive agreement with Qiagen LLC, effective March 8, 2020.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the reporting period. However, it discloses specific financial terms related to the terminated agreement:
- Upfront License Fee and Prepaid Royalties: $40 million received by Natera.
- Tiered Royalties: $5 million received by Natera.
- Refundability: All or a portion of the prepaid royalties may be refundable depending on the outcome of termination discussions.
Material Changes
The primary material change is the termination of the license, development, and distribution agreement dated March 9, 2018. This action was triggered by Qiagen's October 2019 announcement that it discontinued development of its proprietary next-generation sequencing (NGS) platform to partner with Illumina, Inc. Natera notified Qiagen of a material breach of the agreement, exercising its right to terminate.
Outlook, Risks, and Contingencies
Management Commentary and Contingencies: The parties are currently in discussions regarding their respective obligations resulting from the termination. The agreement's termination provisions allow for monetary payment by the breaching party in certain circumstances. There is a contingency regarding the potential refund of prepaid royalties.
Risks: The termination eliminates the planned development and distribution of Natera's NGS-based genetic tests on Qiagen's platform in certain global countries. The final financial impact depends on the resolution of ongoing discussions regarding refunds and breach payments.
Investor Verification Checklist
- Verify the outcome of ongoing discussions between Natera and Qiagen regarding the refund of the $40 million in prepaid royalties.
- Confirm whether Natera will pursue monetary damages for Qiagen's material breach beyond the potential royalty refund.
- Assess the impact of losing the Qiagen distribution channel on Natera's global expansion strategy for NGS-based tests.
- Review the full text of the Agreement (Exhibit 10.1 to the 2018 10-Q/A) for specific termination clauses and refund conditions.